Health TrialsbyHealthPanel

Cannabis and Opioid Use Disorder

ConditionOpioid Use Disorder
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-55
SponsorShanna Babalonis, PhD

About this trial

This study plans to enroll participants with opioid use disorder who are not currently seeking treatment to assess the effects of cannabis on opioid withdrawal and other related outcomes.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Current opioid use disorder

Disqualifiers

Current medical conditions that require medical management

Trial design

Design model

Crossover

Treatments tested in this trial

  • Inhaled vaporized cannabis

    Drug

    Double-blind cannabis and placebo doses, administered through vaporizer

  • Intransal opioid

    Drug

    Double-blind opioid and placebo doses, administered intranasal route

Treatment groups

15 Participants
are divided into 2 treatment groups
Group A: Intranasal Opioid AgonistExperimental treatment 2 interventions
Group B: Vaporized cannabisExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Change from Baseline - Opioid Withdrawal Severity - Visual Analog Scale (VAS)

Subjective ratings of opioid withdrawal severity on visual analog scale (scale 0-100; 0 = not at all, 100 = extremely)

Time frame
Change from baseline

Secondary outcomes

1

Change from Baseline - Opioid Drug Liking - Visual Analog Scale (VAS)

Subjective ratings of drug liking on visual analog scale (scale 0-100, 0 = not at all, 100 = extremely)

Time frame
Change from baseline
2

Change from Baseline - Respiration

Physiological monitoring of respiration rate (breaths per minute)

Time frame
Change from baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Shanna Babalonis, PhD

Lead sponsor

University of Kentucky

Sponsor institution

National Institute on Drug Abuse (NIDA)

Collaborator

Source ClinicalTrials.gov
Apply now